Under the Paperwork Reduction Act of 1995, no persons are required to res

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number 10743389
Filing Date 2003-12-22
First Named Inventor | Keller Art Unit |
Examiner Name |
Autorous Docket Number |
Autorous Dock

U.S.PATENTS Remove Pages, Columns, Lines where Examiner Cite Kind Name of Patentee or Applicant Patent Number Issue Date Relevant Passages or Relevant Initial* Code¹ No of cited Document Figures Appear 5148546 1992-09-15 Riodoett 5404543 1005.04.04 Faucher, et al. 3 6330639 R1 2001-12-11 Fanning, et al. 6657634 2003-12-02 Sinclair, et al. 5 5623647 1997-04-22 Maitra, et al. 6 R2 2004-06-10 6776787 Groon 6996441 R1 2006-02-07 Tobias 8 6704877 R2 2004-03-09 Cline, et al.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10743369
Filing Date		2003-12-22
First Named Inventor Keller		r
Art Unit		
Examiner Name		
Attorney Docket Number		AU920030889US1

	9	6834353	B2	2004-12-21	Smith, et al.			
	10	7000130	B2	2006-02-14	Adachi			
If you wis	h to a	d additional U.S. Pater		,	ease click the Add button.	Add		
			U.S.P	ATENT APPLI	CATION PUBLICATIONS	Remove		
		Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear					
	1	20030210247	A1	2003-11-13	Cui, et al.			
	2	20040044914	A1	2004-03-04	Gedeon			
	3 20040083478 A1 2004-04-29 Chen, et al.		Chen, et al.					
	4	20020004913	A1	2002-01-10	Fung			
	5	20040236896	A1	2004-11-25	Kanapathippillai, et al.			
	6	20040260957	A1	2004-12-23	Jeddeloh, et al.			
If you wish to add additional U.S. Published Application citation information please click the Add button. Add								
FOREIGN PATENT DOCUMENTS Remove								

Ts	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	Name of Patentee or Applicant of cited Document	Publication Date	Kind Code ⁴	Country Code ² j	Foreign Document Number ³	Cite No	Examiner Initial*
-							1	
	Add	lease click the Add button	information p	citation	atent Document	dd additional Foreign F	n to ac	If you wish
	Remove	CUMENTS	RATURE DO	NT LITE	NON-PATE			
T5	xaminer Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.				Examiner Initials*			
T							1	
	outton Add	ion please click the Add b	ation informat	ment cit	nt literature docu	dd additional non-pater	to ac	If you wish
		E	R SIGNATUR	AMINE	EX			
		Date Considered				ature	Signa	Examiner
h			tion is in conf	not cita	dered, whether or	nitial if reference consid	ER: In	*EXAMINI

See Kind Codes of USPTO Patent Documents at www.USPTO.QDV or MPEP 601.04. * Enter office that issued the document, by the two-letter code (WIPO Standard ST3.). * For Lapranese patent documents, the advantage on the parent or the Empart or many precised the sensal number of the patent for sensal for sensal considerable or the patent considerable or the patent or th

Attorney Docket Number A

ALIG20030880LIS1

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sec 37 CFR 197(eVI).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(c).

See attached certification statement.

Diagon one 37 CER 1 07 and 1 98 to make the appropriate colortion(c)

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

□ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Mitch Harris#42,638/	Date (YYYY-MM-DD)	2006-06-08				
Name/Print	Andrew Mitchell Hamis	Registration Number	42638				

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, U.S. operationed for Commence, P. 0. Bot 1450, Alexandria, V.S.231.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.231.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2044 and 2046. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the state of the s
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.